openPR Logo
Press release

Hepatocellular Carcinoma Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

05-15-2018 05:02 PM CET | Health & Medicine

Press release from: Precision Business Insights

Hepatocellular Carcinoma Disease Pipeline Drugs

Hepatocellular Carcinoma Disease Pipeline Drugs

Hepatocellular Carcinoma Disease Pipeline Drugs Assessment Overview:

Hepatocellular Carcinoma is the most common primary tumour of liver. It is caused to the people who are having underlying liver diseases such as hepatitis B or C virus, Cirrhosis and non – alcoholic fatty liver disease. HCC does not cause any symptoms in the early stages of diseases. Some of the symptoms of HCC includes loss of appetite, weight loss, nausea and vomiting, upper abdominal pain and swelling, jaundice, white and chalky stools etc.
HCC can be prevented by taking hepatitis vaccination. HCC can be diagnosed by blood tests, CT scan, MRI, Liver tissue biopsy. General treatment of HCC includes liver transplantation, surgery, Radiation Therapy, Transcatheter Arterial Chemoembolization, Brachytherapy, Targeted Drug Therapy, Palliative care

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/hepatocellular-carcinoma-disease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx

Segmentation:
By Trial Phase, Hepatocellular Carcinoma pipeline drugs are segmented as:
• Preclinical Trials
• Phase 1
• Phase 2
• Phase 3
• Phase 4
By Company, Hepatocellular Carcinoma pipeline drugs are segmented as:
• Eisai Inc.
• Astellas Pharma Inc
• Pfizer
• Astra Zeneca
• Hoffmann-La Roche
• GlaxoSmithKline
• Oncozyme Pharma Inc.
• Novartis Pharmaceuticals
• Eli Lily & Co
• Bristol-Myers Squibb
By Drugs, Hepatocellular Carcinoma pipeline drugs are segmented as:
• Regorafenib
• SorafenibTosylate
• Lenvatinib
• Sorafenib
• Pentamidine
• Brivanib
• Capecitabine
• Ramucirumab
• Others
By Route of Administration, Hepatocellular Carcinoma pipeline drugs are segmented as:
• Oral
• Parenteral

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/hepatocellular-carcinoma-disease-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu

Space Analysis:
• In September 2017, Onxeo S.A released the top line results of phase III Relive trial of Livatag (Doxorubicin Transdrug) in adult patients with unresectable hepatocellular carcinoma (HCC). Results determined that the overall safety and tolerability of Livatag in Relive was favourable with fully manageable toxicity profile in both groups of Livatag20mg/m² and 30mg/m²) and also in patients who has undergone longest treatment period. Thw overall tolerability was comparable to the one observed in comparative group.
• In July 2017, Eisai Inc submitted a supplemental New Drug Application to U.S. FDA for first line use of its lenvatinib (Lenvima) a multiple receptor tyrosine kinaseinhibitor(including fibroblast growth factor receptors [FGFR] 1 – 4), in patients with hepatocellular carcinoma (HCC).

Report Description:
Hepatocellular Carcinoma Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Hepatocellular Carcinoma treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Hepatocellular Carcinoma disease pipeline drugs development. This report studies the dynamics of the Hepatocellular Carcinoma Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Hepatocellular Carcinoma disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/hepatocellular-carcinoma-disease-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3

Key Features of the Report:
• Provides the information related to universities and research institutes working in the therapeutics development
• Report comprehensively covers the all active and discontinued studies
• Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
• Presents the prominent targets for drug development in each stage of clinical trial
• Provides the in-depth analysis on the each drug candidates in the clinical trial phases

Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/hepatocellular-carcinoma-disease-pipeline-drugs-assessment/

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,
152 – 160 City Road,
London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hepatocellular Carcinoma Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018 here

News-ID: 1050646 • Views: 301

More Releases from Precision Business Insights

Corporate Training Market Segments, Top Key Players, Drivers And Trends 2022
Precision Business Insights published a research report on "Corporate Training Market: By Training Type (Classroom, E-Learning & Webcast), By End User (Software & Technology, Healthcare, Retail, Bank, Finance, & Insurance, Manufacturing, Government & Defense, Telecom & Others) - Global/Region/Country Forecast to 2028" In recent years, corporate training has evolved significantly to include more than simply new employees, salespeople, and leaders. Corporate trainers and learning and development specialists are viewed as commercial
UK Private Healthcare Market Business Opportunities And Regional Outlook 2022
Precision Business Insights published a research report on "UK Private Healthcare Market : By Service Type (Private Acute Care Hospitals, Private Patient Care Clinics, Private Specialist Services, Private Diagnostics and Imaging Centers, Private Urgent Care Centers, and Others), By Specialty (Trauma and Orthopedics, General Surgery, Oncology, Maternity and OB-Gyn, Cardiology, Urology, and Others), End Users (International Tourists, NHS Referrals & PMI, and Self-pay Individuals) - Global/Region/Country Forecast to 2028" A
Rice Bran Oil Market | Size, Growth, Trends And Forecast 2022-28
Precision Business Insights published a research report on "Rice Bran Oil Market: By Application (Food & Beverages, Cosmetics, Others), By End User (Super & Hyper Markets, E-Commerce, Others) - Global/Region/Country Forecast to 2028" Rice bran oil is an edible vegetable oil derived from the rice's outer brown coat. It is high in vitamin E, antioxidants, & natural bioactive phytoceuticals such oryzanol, tocopherols, tocotrienols, as well as lecithin, and has a moderate
Pneumatic Tools Market Size, Share, Growth | Global Report 2028
Precision Business Insights published a research report on "Pneumatic Tools (Hammers & Drills) Market: By Product Type [Hammers (Pneumatic Hammer, Hydraulic Hammer, Concrete Hammer), Drills (Hand held Surface Rock drill, Drill Rigs & Cluster Drills)] - Global/Region/Country Forecast to 2028" Compressed air (as it works by the force of air) powers pneumatic tools; compressed air is supplied by an air compressor. To put it another way, pneumatic devices are driven by

All 5 Releases


More Releases for Hepatocellular

Hepatocellular Carcinoma Drugs Market Outlook, and Opportunity Analysis, 2018-20 …
Hepatocellular carcinoma (HCC) is a major type of primary liver cancer that arises from the liver cells or hepatocytes. The disease is found to occur mainly in patients with hepatitis B, hepatitis C, cirrhosis, obesity, and diabetes. Diagnosis of hepatocellular carcinoma is mainly done by imaging tests such as ultrasound, MRI, CT scan, and liver biopsy. Treatment for hepatocellular carcinoma mainly includes radiation therapy, ablation therapy in addition to chemotherapy
Hepatocellular Carcinoma Drugs Market Opportunity Analysis, 2018-2026
Hepatocellular carcinoma (HCC) is a major type of primary liver cancer that arises from the liver cells or hepatocytes. The disease is found to occur mainly in patients with hepatitis B, hepatitis C, cirrhosis, obesity, and diabetes. Diagnosis of hepatocellular carcinoma is mainly done by imaging tests such as ultrasound, MRI, CT scan, and liver biopsy. Treatment for hepatocellular carcinoma mainly includes radiation therapy, ablation therapy in addition to chemotherapy
Hepatocellular Carcinoma HCC Treatment Market: Global Forecast over 2026
Hepatocellular carcinoma (HCC) is also known as malignant hepatoma. HCC is the major malignancy of the liver and is found to occur mainly in patients with chronic liver diseases and cirrhosis. The cells of origin of HCC are the hepatic stem cells, although this remains the subject of investigation. The hepatic tumors proliferates with local expansion, spreading in intrahepatic region and finally distant metastases. The uncommon hepatocellular carcinoma is anticipated
Market Overview of Hepatocellular Carcinoma Research and Detailed Forecast 2017
Pune, India, 8th December 2017: WiseGuyReports announced addition of new report, titled “Hepatocellular Carcinoma - Pipeline Review, H2 2017”. Summary Hepatocellular carcinoma (HCC) is a type of cancer originates from a liver cell (hepatocyte) which becomes cancerous. This type of cancer occurs more often in men than women. Symptoms include abdominal pain or tenderness, especially in the upper-right part, easy bruising or bleeding, enlarged abdomen and yellow skin or eyes (jaundice). The
Hepatocellular Carcinoma Global Clinical Trials Review H2 2017
ReportsWeb.com published “Hepatocellular Carcinoma Global Clinical Trials Review H2 2017” from its database. The report reviews top companies involved and enlists all trials pertaining to the company. Report provides latest news for the past three months. Original Content: Publisher's clinical trial report, "Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2017" provides an overview of Hepatocellular Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatocellular
Trends in the Hepatocellular Carcinoma HCC Treatment Market 2016-2026
Hepatocellular carcinoma (HCC) is also known as malignant hepatoma. HCC is the major malignancy of the liver and is found to occur mainly in patients with chronic liver diseases and cirrhosis. The cells of origin of HCC are the hepatic stem cells, although this remains the subject of investigation. The hepatic tumors proliferates with local expansion, spreading in intrahepatic region and finally distant metastases. The uncommon hepatocellular carcinoma is anticipated